secwatch.observer — SEC 8-K summary
======================================

Issuer:     KIORA PHARMACEUTICALS INC (KPRX)
CIK:        0001372514
Form:       8-K
Filed at:   2024-11-08T23:59:59+00:00
Accession:  0001372514-24-000121
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiora Q3 net loss $3.4M; cash $29M; advancing two Phase 2 retinal trials
------------------------------------------------------------------------

- Cash and equivalents $29.0M at Sept 30, plus $1.8M collaboration receivables; runway into 2027.
- Net loss $3.4M vs $5.8M in Q3 2023; decrease due to -$1.1M non-cash change in contingent consideration.
- R&D expenses net $1.3M after $0.9M Théa reimbursement; G&A flat at $1.4M.
- IND approved for ABACUS-2 Phase 2 study of KIO-301 in retinitis pigmentosa; first patient dosing in 2025.
- Phase 2 KLARITY trial of KIO-104 designed; submission for approval on track for Q4 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372514/000137251424000121/0001372514-24-000121-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372514/000137251424000121/kprx-20241108.htm
  HTML page:      https://secwatch.observer/filing/0001372514-24-000121

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer